SLC7A5 antibody - N-terminal region (ARP63651_P050)
- Known as:
- SLC7A5 (anti-) - N-terminal region (ARP63651_P050)
- Catalog number:
- arp63651_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- SLC7A5 antibody - N-terminal region (ARP63651_P050)
Related genes to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
- Gene:
- SLC7A5 NIH gene
- Name:
- solute carrier family 7 member 5
- Previous symbol:
- -
- Synonyms:
- LAT1, E16, D16S469E, MPE16, CD98
- Chromosome:
- 16q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-28
- Date modifiied:
- 2016-10-05
Related products to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
Related articles to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
- L-type amino acid transporter 1 (LAT1), which controls the neutral amino acid uptake across the cell membranes, has been frequently overexpressed in various human cancers. Overexpression of LAT1 is associated with higher proliferation and shorter patient survival in tumors. Here, upregulated LAT1 expression was observed in patient-derived canine bladder cancers (BCs), and a small-molecule LAT1 inhibitor (JPH203) successfully reduced BC tumor growth both in vitro and in vivo. Patient-derived cancer cells were collected from dogs with naturally occurring tumors at veterinary clinics in Japan, and the 2.5D cancer organoid culture system was generated following our previous studies. Compared with other canine cancers or normal bladder cells, the increased LAT1 expression was observed in 2 strains of BC organoids. JPH203 inhibited boronophenylalanine (BPA) uptake activity by more than 90% and suppressed cell proliferation dose-dependently. Deprivation of BPA uptake activity by JPH203 also regulated the phosphorylation of mTOR-related proteins. Furthermore, intraperitoneal administration of JPH203 decreased the growth and tumor weight of BC organoid-derived xenograft in immunodeficient mice with an induction of apoptosis and a decrease in LAT1 expression compared to vehicle-administered mice. Therefore, the present study demonstrates that JPH203 exerts anti-tumor effects in canine BC through modulation of the mTOR signaling pathway and supports further investigation of LAT1-targeted therapy for canine BC. - Source: PubMed
Publication date: 2026/08/27
Yu Ting-WeiKawahashi MinamiGoda FumiyaKanaya AmiElbadawy MohamedEndou HitoshiIde ShoichiroYamawaki HideyukiKaneda MasahiroAbugomaa AmiraUchide TsuyoshiUsui TatsuyaSasaki Kazuaki - Optimal fetal growth in small ruminants fundamentally depends on the active transport of nutrients across the maternal-fetal interface. Although macroscopic variations in placental dynamics are known, the molecular mechanisms linking maternal reproductive status to placental nutrient transport pathways remain poorly defined. This study examined the influence of maternal parity on lamb birth metrics, neonatal morphological traits, serum amino acid concentrations, and the relative expression profiles of amino acid transporter genes in the cotyledons of indigenous Awassi sheep. Forty-two pregnant Awassi ewes were assigned to two experimental groups: mature young adult primiparous ( = 21; 20.4 ± 0.8 months of age; 1st gestation) and multiparous ( = 21; 38.2 ± 1.2 months of age; 2nd or 3rd gestation). Following natural singleton deliveries, phenotypic measurements and blood samples were collected from a representative cohort of ewes and their offspring ( = 14 pairs per parity). Total hydrolyzed serum amino acid profiles were quantified using gas chromatography-mass spectrometry. Relative mRNA expression levels of five specialized transporter genes in harvested cotyledon tissues were evaluated by quantitative real-time PCR. Lambs born to multiparous ewes had higher birth weights, wither heights, and body circumferences than those born to primiparous ewes ( < 0.05). Fold change in the expression of all target genes (, , , , and ) in the cotyledonary tissues of multiparous ewes was increased ( < 0.05). Multiparous lambs had higher circulating concentrations of alanine, leucine, glycine, phenylalanine, histidine, lysine, and tyrosine, resulting in a higher total systemic amino acid concentration ( = 0.001). In contrast, primiparous lambs had higher concentrations of aspartic acid and glutamic acid ( < 0.05). In conclusion, parity-dependent regulation of cotyledonary amino acid transporters is a primary driver of prenatal resource allocation. Mature multiparous ewes upregulate essential transport machinery to clear nutrients from maternal circulation and concentrate them within the fetus, optimizing neonatal growth and structural development. - Source: PubMed
Publication date: 2026/08/28
Bolaji Umar-Faruq OAboragah Ahmad AAljumaah Riyadh SAl-Baadani Hani HAl-Garadi Maged AOlarinre Isiaka OAl-Badwi Mohammed ABa-Awadh Hani AAlhidary Ibrahim AAlharthi Abdulrahman S - Endometriosis is a multifaceted disease, causing debilitating pelvic pain in some patients, while being completely asymptomatic in others. The pathophysiology of endometriosis pain is not well understood and poorly correlated to stage. We hypothesized that this clinical heterogeneity may be explained by examining differences in gene expression. We performed RNA sequencing of 27 formalin-fixed, paraffin-embedded peritoneal biopsies from 9 symptomatic (Sx) and 10 asymptomatic (ASx) subjects. 890 genes were differentially expressed between Sx and ASx samples. Of these, the most significant including genes involved inflammatory signaling (IL16, IL17RA, JAK3, SMPD3, RELT), cell adhesion (OLFML1, CDON, VCAN), and neuromodulation (SEMA6D, ADRA2C, SLC7A5). Gene Set Enrichment Analysis identified functional enrichment in 22 gene ontology (GO) pathways, of which 7 represented immunologic pathways. Weighted Gene Correlation Network Analysis (WGCNA) identified 11 co-expression modules significantly correlated with symptomaticity, including one module strongly enriched for immunologic/inflammatory functions. Of all molecules identified as associated with pain, IL16 expression also correlated with symptom severity when cases were stratified into mild vs. severe pain based on clinical criteria. These findings suggest that endometriotic lesions of symptomatic subjects are characterized by distinct molecular signatures, including altered expression of inflammatory pathways, highlighting potential mechanisms underlying symptom variability and identifying candidate pathways for future therapeutic interventions. - Source: PubMed
Publication date: 2026/09/10
Mamillapalli RamanaiahLi Howard JApelian ShantKumar MonishWang Sarah FPondugula NishitaCampos Gabriela de QueirozSayeed SumaiyaCho YongheeTaylor Hugh S - To elucidate the role and molecular mechanism of the ERα36-SLC7A5/LAT1 signaling axis in the malignant progression of cervical cancer and its sensitivity to boron neutron capture therapy (BNCT). - Source: PubMed
Publication date: 2026/08/18
Zhang LiliQuan RuiHuang HefaWang WeiZhang LuGu LongDai Zhongying - Cisplatin-based chemotherapy responses are highly heterogeneous across cancers, with the mechanisms governing drug sensitivity remaining incompletely understood. Using genome-wide CRISPR-Cas9 knockout screening, we systematically characterized regulators of cisplatin response and uncovered a counterintuitive finding: mTOR inhibition promotes cisplatin tolerance, contradicting the canonical view that PI3K-AKT-mTOR activation confers chemoresistance. Mechanistically, both mTOR suppression and cisplatin treatment converge to activate cytoprotective autophagy, which enhances cancer cell survival under therapeutic stress. The amino acid transporter SLC7A5 was identified and validated as a key integrator of the mTOR-autophagy axis that modulates cisplatin sensitivity. SLC7A5 expression positively correlates with cisplatin sensitivity across cancer cell lines, and its downregulation is associated with cisplatin resistance in multiple cancer types, supporting its potential as a mechanistically grounded predictive biomarker. Translationally, leucine supplementation sensitizes cancer cells to cisplatin in an SLC7A5-mTOR-autophagy-dependent manner. Collectively, our study defines a novel mTOR-autophagy adaptive loop governing cisplatin tolerance, positions SLC7A5 as a central regulatory node with both biomarker and therapeutic target value, and proposes leucine supplementation as a simple, translatable strategy to improve cisplatin efficacy in SLC7A5-expressing tumors. - Source: PubMed
Publication date: 2026/08/22
Rao PengchengZhang TairanLi JuWei WeidengXia XiaoqiangChen QianmingXu XiaopingFeng Xiaodong